Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RAPT RAPT Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RAPT
Price (delayed)
$0.8385
Market cap
$110.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.48
Enterprise value
$54.5M
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
Highlights
The debt is down by 39% year-on-year and by 15% since the previous quarter
RAPT's EPS is up by 22% since the previous quarter and by 19% year-on-year
RAPT's equity is up by 36% year-on-year but it is down by 7% since the previous quarter
Key stats
What are the main financial stats of RAPT
Market
Valuations
Earnings
Shares outstanding
132.29M
Market cap
$110.92M
Enterprise value
$54.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$122.85M
Net income
-$116.51M
EBIT
-$116.51M
EBITDA
-$113.03M
Free cash flow
-$108.69M
Per share
Balance sheet
Liquidity
EPS
-$2.48
EPS diluted
-$2.48
Free cash flow per share
-$0.5
Book value per share
$1.34
Revenue per share
$0
TBVPS
$0.87
Total assets
$187.57M
Total liabilities
$10.2M
Debt
$3.84M
Equity
$177.37M
Working capital
$174.52M
Debt to equity
0.02
Current ratio
21.11
Quick ratio
20.66
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-70.2%
Return on equity
-81.5%
Return on invested capital
-157.7%
Return on capital employed
-65.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RAPT stock price
How has the RAPT Therapeutics stock price performed over time
Intraday
3.66%
1 week
11.28%
1 month
4.67%
1 year
-79.75%
YTD
-46.93%
QTD
-31.27%
Financial performance
How have RAPT Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$122.85M
Net income
-$116.51M
Gross margin
N/A
Net margin
N/A
RAPT's operating income is up by 10% QoQ and by 4% YoY
The net income has grown by 10% from the previous quarter
Price vs fundamentals
How does RAPT's price correlate with its fundamentals
Growth
What is RAPT Therapeutics's growth rate over time
Valuation
What is RAPT Therapeutics stock price valuation
P/E
N/A
P/B
0.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RAPT's EPS is up by 22% since the previous quarter and by 19% year-on-year
The P/B is 82% lower than the 5-year quarterly average of 3.5 and 11% lower than the last 4 quarters average of 0.7
RAPT's equity is up by 36% year-on-year but it is down by 7% since the previous quarter
Efficiency
How efficient is RAPT Therapeutics business performance
The ROIC has plunged by 67% YoY but it has grown by 18% from the previous quarter
The return on equity has grown by 18% since the previous quarter but it has declined by 12% year-on-year
RAPT's ROA is up by 15% QoQ but it is down by 11% YoY
Dividends
What is RAPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RAPT.
Financial health
How did RAPT Therapeutics financials performed over time
RAPT Therapeutics's total liabilities has plunged by 80% from the previous quarter and by 59% YoY
The total assets has contracted by 22% from the previous quarter but it has grown by 20% YoY
The debt is 98% smaller than the equity
RAPT Therapeutics's debt to equity has shrunk by 60% YoY
The debt is down by 39% year-on-year and by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.